Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Apollo Endosurgery, Inc. APEN
$10.00
На 18:01, 12 мая 2023
-5.00%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
579718970.00000000
-
week52high
10.30
-
week52low
3.49
-
Revenue
76856000
-
P/E TTM
-8
-
Beta
2.32304400
-
EPS
-1.06000000
-
Last Dividend
0.00000000
-
Next Earnings Date
31 июл 2023 г. в 20:00
Описание компании
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, as well as delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands. Additionally, the company offers X-Tack Endoscopic HeliX Tacking System, a suture-based device for closing and healing defects in the lower and upper gastrointestinal tract. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Australia, Costa Rica, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Stephens & Co. | Overweight | Overweight | 04 мая 2022 г. |
| Stifel | Buy | Buy | 23 февр 2022 г. |
| Cowen & Co. | Outperform | 15 дек 2021 г. | |
| Stifel | Buy | 09 дек 2021 г. | |
| Stephens & Co. | Overweight | 09 сент 2021 г. | |
| Stifel | Hold | Buy | 04 янв 2023 г. |
| Lake Street | Hold | Buy | 30 ноя 2022 г. |
| Cowen & Co. | Market Perform | Outperform | 23 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| McGaughy R Kent Jr | A | 3687781 | 1465770 | 28 дек 2022 г. |
| McGaughy R Kent Jr | A | 1310701 | 586308 | 28 дек 2022 г. |
| McGaughy R Kent Jr | A | 675181 | 146577 | 28 дек 2022 г. |
| CPMG Inc | A | 3687781 | 1465770 | 28 дек 2022 г. |
| CPMG Inc | A | 1310701 | 586308 | 28 дек 2022 г. |
| CPMG Inc | A | 675181 | 146577 | 28 дек 2022 г. |
| Black Jeffrey G. | D | 332650 | 15060 | 04 ноя 2022 г. |
| Black Jeffrey G. | D | 347710 | 6190 | 05 авг 2022 г. |
| O'KEEFE SHARON | A | 17028 | 17028 | 05 авг 2022 г. |
| O'KEEFE SHARON | A | 18576 | 18576 | 05 авг 2022 г. |
Новостная лента
Buy-rated Boston Scientific's $615 million takeover of Apollo Endosurgery is a positive, says Needham
Market Watch
29 ноя 2022 г. в 12:00
Boston Scientific Corp.'s BSX, +0.88% $615 million acquisition of Apollo Endosurgery Inc. APEN, +65.50% announced earlier is complementary to the former's endoscopy franchise, as it leverages its gastroenterologist call point while offering the potential for it to expand into surgical endoscopy and bariatric surgery, Needham analysts aid Tuesday. The deal is expected to have no material impact on Boston Scientific's 2023 per-share earnings but to boost it after that.
Apollo Endosurgery Stock Soars on Buyout Buzz
Schaeffers Research
29 ноя 2022 г. в 10:50
Apollo Endosurgery Inc (NASDAQ:APEN) stock is soaring, up 63.4% at $9.80 at last glance, after news that Boston Scientific Corp (BSX) will acquire the medical equipment name for $417 million.
Boston Scientific to acquire Apollo Endosurgery for $615 million in cash
Market Watch
29 ноя 2022 г. в 07:13
Boston Scientific Corp. BSX, -0.82% said Tuesday it has agreed to acquire Apollo Endosurgery Inc. APEN, for $10 a share, or about $615 million in cash. The news sent Apollo's stock, which closed Monday at $6, up 61% in premarket trade.
Apollo Endosurgery, Inc. (APEN) Q3 2022 Earnings Call Transcript
Seeking Alpha
01 ноя 2022 г. в 22:18
Apollo Endosurgery, Inc. (NASDAQ:APEN ) Q3 2022 Earnings Conference Call November 1, 2022 4:30 PM ET Company Participants Matt Kreps – Investor Relations Chas McKhann – Chief Executive Officer Jeff Black – Chief Financial Officer Conference Call Participants Mathew Blackman – Stifel Matt Hewitt – Craig-Hallum Capital Frank Takkinen – Lake Street Capital Josh Jennings – Cowen Simran Kaur – Piper Sandler Operator Good afternoon, ladies and gentlemen. And welcome to the Apollo Endosurgery Third Quarter 2022 Results Call.
Apollo Endosurgery to Report Third Quarter Results on November 1, 2022
Accesswire
18 окт 2022 г. в 08:00
AUSTIN, TX / ACCESSWIRE / October 18, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the third quarter ended September 30, 2022 on Tuesday, November 1, 2022, after market close. In conjunction with the release, Apollo will host a live webcast audio call with presentation slides at 3:30 p.m.